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Plasma Renln Activity (PRA) end Acute 
Myocardial Infarction (AMI) - More Evidence for 
a Positive Anoc lMIon  
J,D. Blumenfeld, M,H, Aldermnn. J,E, ~;ealey, H. Cohen, J,H, Laragh, New 
York Hosplh~l.Comell Me¢tlcnl Center, NY, NY; Albert Elnsfeln Collng~ of 
Medicine. Bronx, NY, USA 
~/~ckgrol~nd: High PRA le Independently associated with Increased risk el MI 
In hypertensives (NEJM 1991; 324:1090), The present study further assesses 
lhe association of PRA to AMI lfl the acute setting, 
Method: Upon entry to the emergency department, prior to any scum treat. 
mant, PRA wee measured aa p~rt of the standard evak,allon of 349 ¢onsocu. 
live patients who ware hospitalized for suepoetad MI, 
Rasultl: Olltgnoels of AMI was confirmed/unconfirmed ,n73/270, These 
grogp~, did nol differ In age (8ft,g :~ 0,2 va 60,1 • 0,g yre,), systolic (143 ± 4 ve 
140 • 2 mm Hg), or diastolic (81 • 2 vs 81 ± 1 mm Hot pressures, Moan PRA 
et entry w~s 3.fold higher In MI (1 1~ vo 3,2 ng/ml/h; p ~ 0,0001), PRA, ae a 
contlnuog~ ved¢lbla, was found tn rngltlverlalo analysts to be lhe prodomln~nt 
Indapendonl risk factor for AMI (p < 0,00001), followed by white race (p - 
0,02), hypertension (p = 0,02), mela gender (p .~ 0,05) end prior CA~Q (p 
• ~ 0,05), controlling for other ri~k lectern including hyperoholesterolemta iNS) 
sad prior drag therapy iNS), Moreover, In a aep~mta multlverieta nalysis 
controlllil~ for other rtsk l~atom, troelmenl with Iong.e0ting dihydropyndlne 
oalelgm blo~Imm was aseo(~let~ with e stgnlIieanl increase In AMI eoml~rod 
to treatment with/I,blo~ker~ (OR ~= 3,~; CI 2,0 to ~,3), 
Corrcltm,on: PRA is considerably higher in AMI and is Independently as. 
~o~laled with increased risk el AMI, These findings give new support to the 
possibility that excessive acllvlty el the renln system in this ac~lta selling, as, 
well a~ in embulMory I~tlents, plays ~ role in palhogsnesis el MI In a eubstan. 
llel fmctlon el l~ltent~, 
• Myo©erdlai Infarction With and Without Coronary 
Artery Disease In Afr ican Americana 
J. Craig, I, Dew.on, C, Crawlord.Green, Ho~..~rtl University, Washington, DC, 
USA 
We have ropo~led previously tram our laboratory regarding African American 
patients with chest pare and myocardial tschemia in the absence el epicardial 
coron~Iry artmy disease (CAD). Individuals with Ih~a syndrome ere clinically in- 
distinguishable from patients with CAB. We studied 153 consecutive patients 
(pie) with acute reyecardial tnlarcllon seen at our hospital from Dec. 1996 to 
July 1997. 44 pts from this group undenNent cardiac catheterizalion and 36 
,~ad CAD deIInnd as greater then 50% luminal narrowing m at least one major 
t~picerdial vessel, 8 had normal coronary arteries (nit. There was no cocaine 
~.~o In either group 
men % women % Imp' ngtdl de~th % DM" % LVH % EF 
Nt' 38 ('~2 283 13 55 50 395 
CAD 42 5B 337 14 55 67 49 6 
'no'm~ll cotonl~nos (Nit, troponm I Itrop), d=~bolos motlitus (OM) 
'there was no statistically significant difference In any of the above van- 
ables between individuals with angiographtcally documented CAD and nor- 
mal corenew arteries. The degree of tropontn elevation did not predict infarct 
s~ze, severity of CAD, or mortality. These data suggest that myocardial is- 
chorale and neeresls c~n occur in the absence of eplcardlal disease and this 
abno~maUty el the mtcrovasculature is indistinguishable lrem "classic" CAD. 
Further prospective evaluation of the identification and optimal therapy of 
these l:~tlents is clearly warranted. 
1~53 Angiotensln Converting Enzyme Inhlbitors 
and Receptor Blockers in Acute Myocardial 
I n fa rc t ion  
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I l l  49-~ Aspir in Does Not Interact With ACE InhlLitors 35-1 
" When Both Are Given Early After Acute 
Myocardial Infarction 
R. LatinL ACE.inhibiter MI Collaborative Group: Marie Nogri Institute, Milano, 
Italy: McMaster Clinic, Hamilton, Ontario, Canada 
Background: Aspirin (ASA) and ACE inhibitors (ACEi) reduce mortality when 
given early alter MI. Although there are pharmacological ways by which ASA 
could antagonize some of the beneficial effects of ACEI (e,g, inhibition of 
synthesis of vesodilating prestaglandlns), evidences from largo controlled 
trials are eonlrovamleL 
Methods: We analyzed the data base el e recently podormod ovendew on 
98483 Individual pl data ellocelad ACEI or no.ACEI within 38 h from the onset 
of ayr,~ptoms ofMI in 4 trials, CCS-1, CONSENSUS II, GIS$1-3 end ISIS-4. 
Re,suits: Out of 96712 pta analyzable, 10228 (10,6%) did not mmlv~ ASA 
at entry. Overall ACEI reduced 30.day mortality from 7.6% to 7,1% (p ,  0,004); 
mortality in pts receiving ASA was reduced by ACEI from §,P.~ to 6.3% (pro. 
portlonal % reduction :t:SD' 0,3 ± 2,7), and in pts not receiving ASA from 
15,1% to 13,0% (proportional % reduction ~SD: 10~ ~ 5,3). Mol~!ity mdt,~. 
lion in 'the 2 groups wee not aigntlioanlly diffamnl (.~.~ for helerot~m~ty --- 0,4), 
The e~lsteoca of an infatuation between ASA and ACEi on ~ y  morality 
wee stag tested by multivariate analysis adju~led lor,~"onfogndlng vanable.a l 
enlry (age, K$ip el~se, heart role): the interaction was not ~latist~¢atty ~ i f .  
teanl (x ~ ~ 0,01), The ril~k el pomlMenl hypolension was increased by ACEI 
from 9,,t% to 1"/,0% in pie with ASA and from t0,0% fo 18~3% in pie w,houl 
ASA, Tl~e ask of renal dyMgncben was increased from 0,6% to 1~3% m ple 
with ASA end from 0,P,~, to t ,4% in p!s withoul ASA, No intero~K~ be~ 
ASA and ACE! we,= found lot these two adverse events both oll unwanate and 
mu!livari~le analysis, 
Coc,¢ft~mns: ASA neither attenuates Ihe n'~rtatity benefit el early ACEI 
alter MI, nor increases the ask ot major adveme events, Therefore, ACEican 
be safety given early oiler MI even when ASA is being given. 
~ 5 0  _~. I~-15---~ E f fe te  o!  Anglotens ln  Conven ing Emcyme 
Inhibition on Cardiopulmonal~/hrcmtllex 
~neitivlty in Patients With Acute Myocardial 
infarct ion 
M, Hikosak~, F, Ygsse, R, Yuyama, 1". Sugiura. 1, Iwaseka. Kansai Me(l~cal 
UnP.'ersl~, Osaka, Jal~n 
Back13round; CardiopulmrJnaW refteses (CP) tonically inhibit sympathet¢ out- 
flow end am blunted in patients with congestive heart failure. However, no 
date are evadable about the effects el angiolensin convemng enzyme (ACE) 
inhibition on CP in patients with acute myocardial iutamt~on (MI). The atre el 
Ihe study wa~ to evaluate the effects of ACE inhibitor (quinapnl) on CP in 
patients with uncomplicated MI. 
Methods: Fifteen patients with uncomplicated MI (group A) undena~ent CP 
sensitivity evaluation 5 days after the onset el MI and alter 10 days el qutnapnl 
therapy. Fifteen additional Mi patients (group B: control group) were evaluated 
at the same time interval before and after placebo administration to i01onttly 
spontaneous CP venation. CP was assessed by the response ot forearm 
vascular resistance induced by towedng central venous pressure through 
lower body negative pressure to-10 mmHg. 
Results: Before quinapfil administration, there were no s~gndmant chtter- 
ences in hemedynamic variables, ejection traction (59 ± 6 vs 60 ± 11%), CP 
(20 "~ 14 vs 14 : 5%), plasma noradrenaline (479 ± 285 vs 354 ± 111 pg/ml) 
and plasma renin activity I1.2 ± 1.1 vs 2.0 ± 1.4 noj'mlff~r) between group A 
and group B. Alter quinapnl administration, CP in group A was signilK:antly 
higher then that in group B (47 ~ 24 vs 24 + 9%, p < 0.05). Moreover, the 
amount ot increase in CP was larger in group A than that in group B (26 ± 21 
vs t0 ± 5, p < 0.05). In group A. plasma noradrenaline decreased (479 
392 pg/ml) and plasma renin activity increased (1.2 ~ 5.7 ng~t/hr), but not 
in greupB. 
Conclusions: Quinapnl improves CP in patients with uncomplicated MI. 
This improvement was associated with a reduction in sympathetic Outflow 
and may contribute to the beneficial effects of ACE inhibitors in patients w~th 
acute MI, 
• Effects of  Early ACE-Inhibition in Patients With 
AMI sad Arterial  Hypertension 
C. Borghi. B. Magnani ~ ,E. AmbresionL On behalf of the SMILE Working 
Group: Department of Internal Medicine. University of Bologna. Italy: 
Department of Cardiology. University of Bologna. Italy 
ACE inhibitors (ACEt) have been demonstrated to be largely effective for 
the treatment of both hypertension and coronary artery disease. The present 
study was carried out as post-hoe analysis of the SMILE data base to evaluate 
the influence el history of arterial hypertension on the efficacy of 6-week treat- 
ment with zofenopril given early (<24 hours) to patients with acute anterior 
myocardial infarction (AMI), The main outcome measures were: 6-week com- 
bined Occurrence of death (D) and severe refractory CHF (S-CHF) as well as 
1-year mortality (1Y-D), Normotenswe (NBP, n.876) and hypertensive (HBP. 
n.566) patients were largely comparable at baseline. In the HBP group the 
6-week prevalence of death (8.2 vs 5.8%), S-CHF (5.8 vs 2.3%) and death + 
S-CHF (14.1 vs 7.9%) was increased when compared with the NBP group (2p 
= 0.001 ) as was 1 -year mortality (19.6% vs 16.2%; 2p = 0.05), 
